Use of a Nutritional Supplement to Treat Diabetic Symptoms in HIV-Infected Adults (NT)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130309095131im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
The purpose of this study is to determine the effectiveness of the nutritional supplement chromium picolinate in improving insulin resistance, a symptom of diabetes, in HIV-infected patients. The ultimate goal is to find a simple therapy that can prevent the development of diabetes in individuals with HIV.
Condition | Intervention | Phase |
---|---|---|
Insulin Resistance HIV Infections |
Dietary Supplement: Chromium piccolinate Dietary Supplement: Chromium Picolinate |
Phase 1 Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
Official Title: | A Novel Therapy for Glucose Intolerance in HIV Disease |
- Improvement in insulin sensitivity [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
Estimated Enrollment: | 40 |
Study Start Date: | November 2005 |
Study Completion Date: | May 2010 |
Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: 1
Double blinded study to assess chromium picolinate's effect on insulin sensitivity in HIV+ subjects
|
Dietary Supplement: Chromium piccolinate
2 tablets per day
Dietary Supplement: Chromium Picolinate
2 tablets per day for 8 weeks
Dietary Supplement: Chromium Picolinate
2 tablets per day
|
Detailed Description:
Insulin resistance occurs when blood glucose levels get too high for the body to respond. Certain anti-HIV drugs are associated with increased insulin resistance and may lead to abnormal fat distribution, hypertension, and type 2 diabetes mellitus. The dietary supplement chromium picolinate has been shown to safely improve insulin sensitivity in patients with type 2 diabetes mellitus with no serious side effects. However, the effects of the supplement have not been thoroughly examined in HIV-infected individuals. This study will determine the effectiveness of chromium picolinate in improving insulin resistance in HIV-infected individuals.
This study will last 2 months. Participants will be randomly assigned to receive either chromium picolinate or placebo once a day for 2 months. Participants will have four overnight visits at the research center and two additional daytime visits for safety monitoring. During the overnight visits, participants will undergo a euglycemic hyperinsulinemic clamp, in which a continuous infusion of insulin is given through a vein and glucose levels are monitored through blood samples taken every 5 to 10 minutes. Fat tissue biopsies will also be conducted at the overnight study visits. During the safety monitoring visits, blood collection will occur for kidney and liver function tests, CD4 count, and viral load assessment.
![](https://webarchive.library.unt.edu/web/20130309095131im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV infected
- Currently taking an anti-HIV drug regimen
Exclusion Criteria:
- Cancer
- Acute illness that would interfere with the study
- Hypogonadism
- Hypothyroidism
- Untreated hypertension
- CD4 count less than 300 cells/mm3
- Viral load greater than 35,000 copies/ml
- Untreated hepatitis C virus infection
- Pregnancy
![](https://webarchive.library.unt.edu/web/20130309095131im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
United States, New York | |
State University of New York/General Clinical Research Center | |
Stony Brook, New York, United States, 11794 | |
General Clinical Research Center at University Hospital | |
Stony Brook, New York, United States, 11794-8154 |
Principal Investigator: | Marie C. Gelato, MD, PhD | State University of New York/General Clinical Research Center |
![](https://webarchive.library.unt.edu/web/20130309095131im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Publications:
Responsible Party: | Marie C. Gelato, MD, PhD, Stony Brook University |
ClinicalTrials.gov Identifier: | NCT00109746 History of Changes |
Other Study ID Numbers: | R21 AT002499-01A1 |
Study First Received: | May 2, 2005 |
Last Updated: | August 23, 2010 |
Health Authority: | United States: Federal Government |
Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):
HIV Treatment Experienced Anti-Retroviral Agents |
Antiretroviral Therapy, Highly Active Picolinic acid Dietary Supplements |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Insulin Resistance Glucose Intolerance Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Hyperinsulinism Glucose Metabolism Disorders |
Metabolic Diseases Hyperglycemia Chromium Picolinic acid Anti-Retroviral Agents Trace Elements Micronutrients Growth Substances Physiological Effects of Drugs Pharmacologic Actions Iron Chelating Agents Chelating Agents Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents |
ClinicalTrials.gov processed this record on March 07, 2013